Jonathan Anderson

Jonathan Anderson

Auto-generated profile, based on publicly available information

Jonathan Anderson

Biology, Lake Forest College, Lake Forest, IL, 60045, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
ASAnna Sandler
Anna Sandler
JAJonathan Anderson
Jonathan Anderson
ABAriane Balaram
Ariane Balaram
YGYoan Ganev
Yoan Ganev
SGSamuel Gascoigne
Samuel Gascoigne
WCWilliam H. Conrad
William H. Conrad
Background:Gene silencing by CpG island hypermethylation often plays a role in colorectal cancer (CRC) progression. Certain regions of the genome, called high confidence differentially-methylated regions (DMRs), are consistently hypermethylated across numerous patient samples. Methods:In this study, we used bioinformatics and bisulfite PCR sequencing of HCT-116 cells to investigate methylation levels at DMRs in the promoters of six genes:DKK3, EN1, MiR34b, SDC2, SPG20, andTLX1. We then investigated whether the anti-cancer drug decitabine, had a demethylating effect at these promoter regions. Results:We found that hypermethylation correlated with lack of transcriptional enhancer binding in these six regions. Importantly, we observed that for all DMRs, decitabine significantly reduced CpG methylation. Decitabine also reduced clonogenic survival, suggesting that there is a correlation between lower CpG island methylation levels and reduced cancerous properties. Conclusions:Our study provided single-nucleotide resolution and revealed hypermethylated CpG sites not shown by previous genome-wide methylation studies. In the future, we plan to perform experiments that demonstrate a causal link between promoter hypermethylation and carcinogenesis and that more accurately model treatments in CRC patients.